Trifecta Capital Advisors LLC Reduces Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Trifecta Capital Advisors LLC trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 33.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 405 shares of the company’s stock after selling 200 shares during the period. Trifecta Capital Advisors LLC’s holdings in IDEXX Laboratories were worth $217,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Mutual of America Capital Management LLC raised its stake in shares of IDEXX Laboratories by 79.6% in the first quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock worth $8,160,000 after buying an additional 8,609 shares during the period. Golden State Wealth Management LLC raised its stake in shares of IDEXX Laboratories by 3,766.7% in the first quarter. Golden State Wealth Management LLC now owns 116 shares of the company’s stock worth $49,000 after buying an additional 113 shares during the period. Plato Investment Management Ltd raised its stake in shares of IDEXX Laboratories by 37.1% in the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock worth $1,310,000 after buying an additional 835 shares during the period. Sagespring Wealth Partners LLC bought a new position in shares of IDEXX Laboratories in the first quarter worth about $229,000. Finally, Genesis Wealth Advisors LLC bought a new position in shares of IDEXX Laboratories in the second quarter worth about $215,000. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Piper Sandler reaffirmed a “neutral” rating and issued a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Weiss Ratings reissued a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Wednesday. UBS Group started coverage on IDEXX Laboratories in a research note on Wednesday, October 1st. They set a “neutral” rating and a $720.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research note on Monday, August 4th. Finally, Leerink Partners lifted their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average target price of $656.50.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $629.91 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $688.12. The stock’s 50 day simple moving average is $637.99 and its two-hundred day simple moving average is $539.07. The company has a market cap of $50.40 billion, a price-to-earnings ratio of 52.45, a PEG ratio of 4.06 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the company posted $2.44 EPS. The company’s revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 406 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the sale, the executive vice president owned 11,287 shares of the company’s stock, valued at $7,336,098.52. The trade was a 3.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the completion of the sale, the director directly owned 262 shares in the company, valued at approximately $169,600.46. The trade was a 89.30% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,057 shares of company stock worth $34,293,468. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.